An Open Label, Two-way Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols in Healthy Volunteers Under Fasted Conditions.

NCT02857361 Phase 2 COMPLETED

The study will look at whether it is preferable to administer two wafers simultaneously or separately.

Details

Lead sponsor	iX Biopharma Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	10
Start date	2016-07
Completion	2016-08

Conditions

• Pain

Interventions

• Sublingual ketamine wafers

Primary outcomes

• Bioavailability — 10 hours
  Plasma concentrations collected for 10 hours after simultaneous wafer administration and sequential wafer administration

Countries

Australia